Avricore Health Achieves Milestones and Outlines UK Expansion Roadmap for HealthTab™ Platform

Why It Matters

The expansion positions HealthTab as a leading POCT solution within the NHS, unlocking new revenue streams and accelerating the shift toward pharmacist‑led preventive care. Success in the UK could catalyze broader adoption of point‑of‑care testing across Europe and North America.

Key Takeaways

• HealthTab screened >3,500 patients in London pharmacies.
• 2,295 HbA1c tests done across 57 sites in one month.
• British Heart Foundation granted $385k for Inclisiran pilot.
• Avricore targets 500 UK sites by mid‑2027.
• 2024 revenue $4.79M, 37% YoY growth.

Pulse Analysis

Avricore Health’s recent milestones signal a decisive pivot from its Canadian base to the UK’s National Health Service (NHS) market. By leveraging the HealthTab platform—an integrated suite of analyzers, cloud software, and quality‑management protocols—the company has demonstrated the scalability of point‑of‑care testing (POCT) in community pharmacies. The pilot’s impressive per‑location test volume, ten times higher than Canadian averages, underscores the untapped demand for rapid diagnostics as pharmacists gain independent prescribing rights.

The strategic roadmap, dubbed "The Path Forward," outlines a phased rollout that could see more than 500 active sites by mid‑2027, tapping into an addressable market of over 10,000 pharmacies across England’s integrated care boards. Funding from the British Heart Foundation for an Inclisiran secondary‑prevention study adds clinical credibility and aligns HealthTab with emerging cardiovascular therapies. Coupled with an independent evaluation by UCLPartners and attention from NHS leadership, these endorsements position Avricore to secure NHS commissioning contracts, a critical revenue driver as subscription fees are slated to commence in late 2026.

From a broader industry perspective, Avricore’s expansion reflects a growing trend toward decentralized diagnostics, driven by regulatory changes that empower pharmacists as frontline prescribers. The company’s emphasis on rigorous quality assurance—partnering with CEQAL and adhering to CDC reference standards—addresses longstanding concerns about POCT accuracy, potentially setting a new benchmark for the sector. If Avricore achieves its profitability target by Q3 2027, it could attract further investment and accelerate the convergence of pharmacy services and digital health analytics across global markets.